Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 4 October 2016, 13:35 HKT/SGT
Share:
    

Source: Eisai
Launch of Uritos Tablets for Overactive Bladder in Thailand

TOKYO, Oct 4, 2016 - (JCN Newswire) - Eisai Co., Ltd. and KYORIN Holdings, Inc. announced today that Eisai's Thai subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched Uritos Tablets (generic name: imidafenacin), a therapeutic agent for overactive bladder, in Thailand.

Uritos was discovered and developed by KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings who subsequently granted Eisai the exclusive rights to develop and market the agent in China, India, Sri Lanka and ASEAN countries in 2009. This marks the first launch of Uritos in a region where Eisai holds marketing rights to the agent.

Overactive bladder (OAB) is a urological condition marked by a frequent, sudden urge to urinate. It is often accompanied by frequent urination and nocturia, and in some cases by urge urinary incontinence. OAB may cause serious issues for patients' quality of life, such as becoming hesitant to go out due to the anxiety of suddenly needing to go to the toilet, or lack of sleep from constantly waking up to use the bathroom at night.

While it is known that OAB becomes more common with age, studies suggest that people with diseases of the brain or spinal cord such as stroke or Parkinson's disease as well as enlargement of the prostate are at high risk of OAB. According to the clinical guidelines for overactive bladder in Japan, the prevalence of OAB in the country ranges from 5 to 20%. Although the prevalence of OAB in Asia is unknown, it was reported that 29.9% of men and 34.7% of women aged over 18 experienced some symptoms of OAB, many of whom did not receive appropriate treatment due to lack of disease awareness.(1)

Uritos is an anticholinergic agent commonly prescribed to treat OAB. It exhibits selective antagonistic effects on M3 and M1 muscarinic subtype receptors to help alleviate the urge to urinate, frequent urination and urge urinary incontinence associated with OAB. The most common side effects are thirst and constipation.

Through this launch, Eisai and Kyorin Pharmacetucial strive to improve QOL and further contribute to increasing the benefits for patients with OAB in Thailand.

(1) About Uritos Tablets (generic name: imidafenacin)

Administered orally twice-daily, Uritos is an anticholinergic agent commonly prescribed to treat OAB. It exhibits selective antagonistic effects on M3 and M1 muscarinic subtype receptors to help alleviate the urge to urinate, frequent urination and urge urinary incontinence associated with OAB. The most common side effects are thirst and constipation.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120

Corporate Communcation, 
President's Office KYORIN Holdings, Inc. 
+81-(0)3-3525-4707 


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 31, 2025 17:27 HKT/SGT
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31, 2025 08:30 HKT/SGT
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
July 31, 2025 08:20 HKT/SGT
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
July 31, 2025 08:10 HKT/SGT
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
July 29, 2025 08:01 HKT/SGT
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
July 25, 2025 12:31 HKT/SGT
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
July 23, 2025 09:07 HKT/SGT
Launch of Beova(R) Tablets in Thailand for Overactive Bladder
July 22, 2025 10:56 HKT/SGT
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025
July 16, 2025 13:50 HKT/SGT
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
July 14, 2025 09:20 HKT/SGT
"URECE" (Dotinurad) Launched in China as a treatment for Gout
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: